VJHemOnc Podcast

Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells

Oct 1, 2020

Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.

20:15

Creator website

Episode guests

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Advancements in CAR-T and cellular therapy include the use of mesenchymal stem cells for graft versus host disease and potential application in COVID-19 inflammatory disease.

Gene-edited effector cell therapy offers the potential to improve T-cell therapies by enhancing potency and creating off-the-shelf T-cells without graft-versus-host disease risk.

Deep dives

Advancements in Cellular Therapy for Hematological Malignancies

The podcast episode explores recent updates in CAR-T and cellular therapy for hematological malignancies. The first discussion focuses on the engineering of T cells and the use of mesenchymal stem cells for treating graft versus host disease (GVHD). The efficacy of CAR-T cell therapy and the use of CRISPR to disrupt genes are highlighted. Additionally, the potential application of mesenchymal stem cells in COVID-19 inflammatory disease is discussed. The second part of the podcast delves into CAR-T cell therapy for multiple myeloma, highlighting studies such as Karma, Cartitude 1, and Evolve that demonstrate high response rates and durable remission durations in a refractory patient population. Lastly, the podcast covers key clinical trials involving CAR-T cell therapy for refractory-diffuse large B-cell lymphoma, including Zuma1, Juliet, and Transcend studies, which show comparable durable responses and acceptable toxicity profiles.

Introduction

5min

Advances in CAR-T and Mesenchymal Stem Cell Therapy for COVID-19 Pneumonia and Multiple Myeloma

3min

CAR-T Cell Therapy in Difficult-to-Treat Patient Populations

7min

CAR-T Cell Therapy Studies and Real-World Responses

2min

Comparison of T-stinlucil and exocaptogen, and discussion on gene-edited effector cell therapy

4min

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer.

In this podcast, Annalisa Ruggeri, MD, of IRCCS OSpedale Pediatrico Bambino Gesu, Noopur Raje, MD, of Massachusetts General Hospital, Matthew Frigault, MD, of Massachusetts General Hospital, and Maksim Mamonkin, PhD, of Baylor College of Medicine discuss key updates and clinical trial results in the field of CAR-T and cellular therapies presented at EBMT 2020.

The post Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells appeared first on VJHemOnc.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

VJHemOnc Podcast

Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

Advancements in Cellular Therapy for Hematological Malignancies

Gene-Edited Effector Cell Therapy: Enhancing T-Cell Potency

Advancements in CAR-T and Cellular Therapy for Hematological Malignancies

Remember Everything You Learn from Podcasts